Press Room

Event

2023 AIChE Annual meeting

Start
Sunday, November 05, 2023 - 09:00
End
Friday, November 10, 2023 - 17:00
Location: Orlando, United States
AIChE 2023 Annual Meeting | Hovione

Meet Hovione team at the 2023 AIChE Annual Meeting and find their exciting presentations and Hovione’s latest research and innovations. The AIChE Annual Meeting is an educational forum covering a wide range of topics relevant to cutting-edge research, new technologies, and emerging growth areas in chemical engineering. We look forward to meeting academic and industry experts and exchanging knowledge.

 

Date: November 5, 2023

Oral Presentation 547b

Title: PAT Development Strategy in the Feed Frame As an Enabler for Faster Continuous Manufacturing Implementation
Presenting Author: Pedro Durão (Senior Scientist II, Modelling & PAT)

3:51 PM - 4:12 PM
Celebration 7 (Convention Level)

Oral Presentation 653f

Title: Modeling Continuous Film Coating Process in Consigma Coater: What Changes?
Presenting Author: Pedro Monteiro (Scientist, Formulation Development)

5:15 PM - 5:36 PM
Celebration 8 (Convention Level)

Oral Presentation 653g

Title: Model-Based Application for a Safe Scale-up and Equipment Selection on a Pressure Generating Pharmaceutical Process
Presenting Author: Frederico Montes (Scientist, Corporate Technical Services)

5:36 PM - 5:57 PM
Celebration 8 (Convention Level)

 

Date: November 6, 2023

Session 113 - Particle Characterization

Chair: Sarang Oka, Continuous Manufacturing Development Engineer

12:30 PM - 3:00 PM
Bayhill 19 (Lobby Level)

Poster Presentation 198d

Title: Development and Application of Residence Time Distribution (RTD) Models for a Continuous Direct Compression Process
Presenting Author: José Granjo (Modelling & PAT Scientist)

3:30 PM - 5:00 PM
Regency Ballroom R/S (Convention Level) 

Poster Presentation 198v

Title: Cryo Jet Milling for Micronization Enhancement of Inhalation Particles
Presenting Author: Inês Gomes (IST), with João Pires, Filipe Vultos, Ricardo Velez (Scientists, Hovione) and Ana Azevedo (IST)

3:30 PM - 5:00 PM
Regency Ballroom R/S (Convention Level)

Poster Presentation 643g

Title: A Template for Investigating NIR Spectroscopy-Based Deviations
Presenting Author: Ankita Naik (Modelling & PAT Scientist, CM Process Development)

5:36 PM - 5:57 PM
Celebration 8 (Convention Level)

 

Date: November 7, 2023

Oral Presentation 500g

Title: Recent Advances in ASD Formulations: Combining Dispersome® Technology with a High-Throughput Screening Setup
Presenting Author: Inês Ramos (Senior Scientist, Formulation Development)

1:08 PM - 1:26 PM
Manatee Spring II (Lobby Level)

Oral Presentation 500h

Title: Amorphous Solid Dispersions By Spray Drying: From Early Formulation to Commercial Lifecycle Management
Presenting Author: José Luís Santos, Director, Technology Intensification

1:26 PM - 1:44 PM
Manatee Spring II (Lobby Level)

Oral Presentation 583a 

Title: Impact of Rheology and Process Variables on the Development and Scale-up of a Drum Filling Process for Dry Powder Inhalers
Presenting Author: Rui Churro (Senior Scientist, Process Development)

3:30 PM - 3:51 PM
Celebration 8 (Convention Level)

Oral Presentation 583d

Title: Droplet to Particle model prediction by coupling solution rheological characterization, CFD and Phase doppler analysis
Presenting Author: Márcia Tavares (Scientist, Process Development)

4:33 PM - 4:54 PM
Celebration 8 (Convention Level)

 

Date: November 8, 2023

Oral Presentation 74c

Title: Bridging Crystallization and Mechanical Properties to Particle Size Reduction Efficiency in Jet Milling Industrial Pharmaceutical Processes
Presenting Author: Gonçalo Marcelo (Scientist, Particle Engineering)

9:00 AM - 9:20 AM
Bayhill 19 (Lobby Level) 

Poster Presentation 303r

Title: Integrating Three-Fluid Nozzle Technology as a QbD Tool for Enhancing Advanced Respiratory Drug Delivery Formulations: A Statistical Modeling Approach 
Presenting Author: Rui Churro (Senior Scientist, Process Development)

3:30 PM - 5:00 PM
Regency Ballroom R/S (Convention Level)

Poster Presentation 84at

Title: Asset Intensification: Application of Modelling Tools and Methodologies from a CDMO Perspective
Presenting Author: Filipe Ataide (Senior Scientist, Technology Intensification)

3:30 PM - 5:00 PM
Regency Ballroom R/S (Convention Level)

 

 

Date: November 9, 2023

Oral Presentation 355e

Title: Controlled Crystallization through Microfluidization As an Alternative Particle Engineering Technology for Inhalation Products
Presenting Author: Gonçalo Marcelo (Scientist, Particle Engineering)

9:24 AM - 9:45 AM
Celebration 8 (Convention Level)

Oral Presentation 649e

Title: Use of Statistical Process Control to Drive Process Improvements in Continuous Manufacturing
Presenting Author: Ankita Naik (Modelling & PAT Scientist, CM Process Development)

4:58 PM - 5:20 PM
Celebration 8 (Convention Level)

 

 

 

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

 

 

Schedule your meeting today 

 

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All